LadRx (STU:CX5) Total Operating Expense: €3.25 Mil (TTM As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:CX5 LadRx Corp STU:CX5
40 GF Score
Price €0.06
View Full Analysis

What is LadRx Total Operating Expense?

LadRx STU:CX5 40 Total Operating Expense is €3.25 Mil as of Mar. 2025. GuruFocus rates STU:CX5 with a GF Score™ of 40/100.

LadRx's Total Operating Expense for the three months ended in Mar. 2025 was €0.67 Mil. LadRx's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 was €3.25 Mil.

LadRx Total Operating Expense Related Terms

LadRx Total Operating Expense Historical Data

* Premium members only.

The historical data trend for LadRx's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LadRx Total Operating Expense Chart

LadRx Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.61 5.29 4.31 3.51 3.46

LadRx Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.77 1.20 0.75 0.64 0.67
STU:CX5
40GF Score
LadRx Corp STU:CX5
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LadRx Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €3.25 Mil mean?
LadRx (STU:CX5) has a Total Operating Expense of €3.25 Mil as of Mar. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on LadRx and its competitors.
Is LadRx's Total Operating Expense too high?
LadRx's current Total Operating Expense is €3.25 Mil. Overall, LadRx has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does LadRx's Total Operating Expense compare to VRTX and REGN?
LadRx's Total Operating Expense of €3.25 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on LadRx and its competitors. LadRx's current Total Operating Expense is €3.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LadRx stock overvalued right now?
LadRx (STU:CX5) has a current Total Operating Expense of €3.25 Mil. The current Total Operating Expense is €3.25 Mil. LadRx's overall GF Score™ is 40/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For LadRx (STU:CX5), the current Total Operating Expense is €3.25 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LadRx Business Description

Address 11726 San Vicente Boulevard, Suite 650, Los Angeles, CA, USA, 90049
LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.
40GF Score

Get the complete analysis for STU:CX5

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.06
Price